MRNA Shares Outstanding
Total shares outstanding each quarter, showing dilution from issuance or reduction from buybacks.
Shares Outstanding
Latest: 399M (2026Q2)
| Period | Value |
|---|---|
| 2019Q3 | 333M |
| 2020Q1 | 371M |
| 2020Q2 | 395M |
| 2020Q3 | 396M |
| 2021Q1 | 402M |
| 2021Q2 | 404M |
| 2021Q3 | 405M |
| 2022Q1 | 398M |
| 2022Q2 | 391M |
| 2022Q3 | 384M |
| 2023Q1 | 405M |
| 2023Q2 | 381M |
| 2023Q3 | 381M |
| 2023Q4 | 381M |
| 2024Q1 | 382M |
| 2024Q2 | 384M |
| 2024Q3 | 399M |
| 2024Q4 | 385M |
| 2025Q1 | 386M |
| 2025Q2 | 388M |
| 2025Q3 | 390M |
| 2025Q4 | 391M |
| 2026Q1 | 395M |
| 2026Q2 | 399M |
* In some reporting periods, diluted weighted-average shares are used instead of period-end shares outstanding. Please verify individual figures against the company's SEC filings.
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
EPS
Free Cash Flow
Gross Margin
FCF Margin
P/E Ratio
Cumulative FCF
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Shares Outstanding
Shares Outstanding
Shares Outstanding
Latest Shares Outstanding: 399M (2026Q2); +2.9% YoY; +2.7% CAGR since 2019Q1 (7.25y).
Across the 26 quarters from 2019Q1 to 2026Q2, Shares Outstanding ranged from 329M in 2019Q1 to 405M in 2021Q3.
Chart and table show the latest 24 of 26 quarters.